Point mutations in GNAS and other genomic and nongenomic aberrations in the tightly regulated GHRH-GHRHR signaling pathway result in persistent cAMP signaling, inducing GH production and somatotroph proliferation, and potentially favoring the development of sporadic somatotroph adenomas. The gene discussed is GHRH; the disease is growth hormone secreting pituitary adenoma 1.